The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer (NCT06477055) | Clinical Trial Compass
CompletedNot Applicable
The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
China43 participantsStarted 2025-12-02
Plain-language summary
This study was a multicenter, real-world observational study aimed at characterizing the genomic landscape of recurrence in patients with EGFR-sensitizing mutation-positive early-stage (clinical stage IB-IIIA) non-small cell lung cancer who received adjuvant osimertinib after surgery.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Informed consent signed;
. Age ≥ 18 years;
. Histologically confirmed diagnosis of non-squamous non-small cell lung cancer;
. Confirmed EGFR sensitive-mutations (exon 19 deletions, 21 L858R point mutations) prior to adjuvant osimertinib therapy;
. Recurrence after/on Osimertinib treatment according to RECIST 1.1;
. NGS gene test report (tumor or blood sample) at the time of recurrence;
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial focused on studying 'recurrence gene profiles' in people who had surgery and took osimertinib — what exactly does that mean, and could understanding my own genetic profile change how my doctor would approach my treatment?
2Since this trial has already completed, has any data or findings been published yet, and if so, what did the results suggest about why some patients on osimertinib after surgery still had their cancer come back?
3This study was specifically for resected non-small-cell lung cancer treated with adjuvant osimertinib — does my particular stage and type of NSCLC match the kind of patients who were enrolled, and is adjuvant osimertinib even a relevant option for me?
4Given that this trial was observational and focused on gene profiling rather than testing a new treatment, would my doctor recommend any kind of genomic or molecular testing for me based on what studies like this are uncovering about recurrence risk?
5Are there currently other active trials or standard-of-care options building on what this type of recurrence gene research is finding, and would my doctor consider any of them worth exploring alongside or instead of the current standard approach?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Recurrence gene profiles
Timeframe: From January 2021 to March 2026, assessed retrospectively from medical records.
. Patients with stage I-III NSCLC whose surgical resection cannot be confirmed;
. Received adjuvant therapy other than that specified in the ADAURA study;
. No NGS test report at recurrence;
. History of other malignant tumors within 2 years;
. Patients assessed by the investigator as unfit for enrollment, such as neurological disorders or metabolic disorders, physical examination or laboratory examination suspected that the patient has a possible disease, or has treatment-related complications High risk etc.